Cell & Gene Therapy

A small biotech with a cancer vaccine and T-cell therapy came to Health Advances for a forecast and business plan in support of its application to be listed on a major stock exchange. The client needed assistance detailing the market context, revenue, clinical costs, and commercialization costs forecasts for its assets. The Health Advances team did deep dives into the epidemiology of each disease, the distribution of patients across lines of therapy, and the oncology market across the US, Europe and Asia. The team synthesized these data into models and detailed documents to be submitted to the stock exchange regulatory body, which allowed our client to highlight its value and facilitated its inclusion on the stock exchange.

A large investor engaged Health Advances to develop an investment strategy for the biotechnology industry. Our team analyzed the landscape of five notable biologic modalities - protein/antibodies, nucleic acid therapies, vaccines, gene therapies, and cell therapies- to prioritize a short-list of the most attractive areas for investment. We characterized the key risks, including scientific/technical and manufacturing; commercial opportunity, including the disruptive potential of the technology and historical/forecasted growth; critical success factors; and financing landscape and investment opportunities. The analysis allowed our client to prioritize the top three most attractive areas for investment.

An early-stage biotech developing a novel gene editing technology engaged Health Advances for an opportunity assessment and detailed clinical development strategy in an orphan disease. Health Advances leveraged insights from clinical and translational KOLs, payers, and regulatory experts across the US, Europe and Japan to understand the evolving treatment landscape and the potential positioning, value proposition, and regulatory requirements for the one-time gene editing technology. The team synthesized this information into a detailed clinical development strategy, outlining timelines, geographies, patient populations, and benchmarks for success, supported by a robust forecast to support the business case.

A company developing a novel gene therapy entering a very competitive market sought to assess the product value proposition, market access and pricing potential and optimize its clinical trial design to set the product up for success in the market. The client used our assessment to determine its next steps with the product and finalize its clinical development plan.